Orbcel-C (Orbsen Therapeutics)

N/A

Report date: 2025/03/27 14:57:14

Base Information

Drug NameOrbcel-C (Orbsen Therapeutics)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsHepatitis, AutoimmuneCholangitis, Sclerosing

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited Kingdom

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesOrbsen Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of Birmingham

Inactive CompaniesN/A

Active IndicationsHepatitis, AutoimmuneCholangitis, Sclerosing

Inactive IndicationsN/A

Other Information

ATC CodeN/A